Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.76% | -91.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.76% | -91.93% | |||
| Cost of Revenue | 7.14% | 162.50% | |||
| Gross Profit | 6.25% | -96.45% | |||
| SG&A Expenses | 7.86% | 13.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -7.84% | 53.08% | |||
| Total Operating Expenses | 7.85% | 22.42% | |||
| Operating Income | -7.85% | -29.48% | |||
| Income Before Tax | -7.85% | -30.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.85% | -30.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.85% | -30.51% | |||
| EBIT | -7.85% | -29.48% | |||
| EBITDA | -7.85% | -26.40% | |||
| EPS Basic | -7.71% | -30.45% | |||
| Normalized Basic EPS | -7.88% | -30.36% | |||
| EPS Diluted | -7.71% | -30.45% | |||
| Normalized Diluted EPS | -7.88% | -30.36% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||